Clinical Trial

Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated June 5, 2026 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial is a non-interventional, observational, multicenter, post-marketing real-world study to evaluate the efficacy and safety of Inaticabtagene Autoleucel Injection in Chinese adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-06; most recent amendment 2024-09-18.
Status change: Not Yet Recruiting → Recruiting 2024-09-18
Trial Details
NCT Number NCT06450067
Lead Sponsor Juventas Cell Therapy Ltd.
Conditions B-cell Acute Lymphoblastic Leukemia
Enrollment 200 participants
Start Date 2024-06-05
Primary Completion 2026-06-05 (estimated)
Study Completion 2029-06-05 (estimated)
Updated on ClinicalTrials.gov 2024-09-19